Financial Data and Key Metrics Changes - The group's revenue increased by 81.9% year over year to approximately $519 million [44] - Adjusted profit from continuing operations grew significantly to about $178 million [44] - The net loss narrowed to about $24.5 million, largely affected by Legend Biotech's performance [44] Business Line Data and Key Metrics Changes - GenScript Life Science Group's revenue grew by 11.3% to about $248 million [46] - ProBio's revenue surged by 511% to around $402 million [44] - Bestime's revenue increased by 8.4% to $28.3 million [52] Market Data and Key Metrics Changes - Revenue from the Americas and European markets grew due to successful execution of global market strategies [49] - The proportion of revenue from international customers for Bestime grew to 23% [52] Company Strategy and Development Direction - The company is focused on expanding market penetration for protein, mRNA, and cell and gene engineering [57] - There is a commitment to advancing CDMO platforms and exploring out-licensing opportunities to maximize R&D benefits [58] - The company is investing in automation and digital transformation to enhance operational efficiency [59] Management's Comments on Operating Environment and Future Outlook - Management anticipates stronger growth in the second half of the year, driven by increased demand and strategic investments [46][55] - The company is confident in achieving margin improvement through enhanced automation and capacity expansion [100] Other Important Information - The company achieved significant ESG milestones, including a silver medal from EcoVadis and an AA rating from MSCI [12] - The cash position stood at $970 million, supporting global expansion and R&D progress [10] Q&A Session Summary Question: ProBio's fee for service revenue and cost of goods sold - Management clarified that excluding the impact of the Lenovo case, fee for service business achieved double-digit growth, and costs were impacted by capacity ramp-up [63][64] Question: Bestime's product breakdown and growth expectations - Management noted that new enzyme products are expected to drive revenue growth in the second half, with confidence in the performance of innovative enzymes [66] Question: Future milestone payments from Lenovo - Management indicated that a milestone payment of $300 million is expected in the second half, with further payments dependent on clinical trial progress [80][82] Question: Global expansion and long-term revenue contribution - Management emphasized the importance of a robust global footprint to ensure speed and reliability for customers, which will support sustainable growth [83][84] Question: Impact of tariffs on profit - Management reported that tariffs had a low impact on profits, less than $4 million, due to the nature of the business and global capacity [90] Question: ProBio's order trends and backlog - Management observed steady growth in orders, with a clear recovery in antibody and protein R&D, and noted that backlog information is no longer disclosed [93][95] Question: Key drivers for Life Science guidance upgrade - Management attributed the guidance upgrade to strong demand momentum and deeper market penetration, while also addressing temporary gross margin impacts [98][100] Question: Future blockbuster products from Bestime - Management confirmed that new products have entered mass production and are expected to drive significant process optimization and cost reduction for clients [109] Question: AI-driven protein and canary business growth - Management highlighted the integration of advanced technology in AI-driven engineering, which plays a critical role in enhancing customer offerings [112]